[e-mail]

Novavax's VLP Technology Is a Game Changer

If it's such a game changer, takeover target why did the insiders just sell hundreds of thousands of shares?

Do you or biomedreports get paid by the company's for these informercial articles? Your pal Havrilla wouldn't reply.

Does Immunomedics' Success Mean Human Genome Sciences' Failure?

Idaho, thanks for the link. I'll take a look.

Charles


NO Hypermetabolic activity on the PET scan,
> his CT scan just an ill defined mass, which was likened to a scar
> from a burn. He feels great, gained weight, HAS HOPE, and while we
> know he's not out of the woods.., are encouraged and looking forward
> to the next meeting in mid-August and moving on from there.
>
> There are a lot of people who may read this, some curious and others
> who've found their way here because they or someone else they know
> and love are ill and looking for help wherever they can find it.
> That's what happened to our family, and when I got here found something
> that at the absolute least is a compassionate way to treat an illness,
> but most importantly is an effective way to fight back against it.
>


>

Does Immunomedics' Success Mean Human Genome Sciences' Failure?

Idaho, if you could post a link to where to find the pancreatic trial comments that would be appreciated.

I still think Garza's comments about the immu lupus data vs hgsi are incredibly misinformed.

Does Immunomedics' Success Mean Human Genome Sciences' Failure?

Actually it was smart to short IMMU at 7.50 on bogus news that fake commentators like Garza touted and here it is a few days later in the 5's. I don't care about immu long term or the cancer program, the stock is overvalued and ran an absurd amount on non news. I was just following the smart money that would have blown out on a release like that.

As far as "humanized" rituxan, great idea, why don't you take a look at Genmab and the trouble they've been having not to mention Genentech has their own humab Rituxan.

Does Immunomedics' Success Mean Human Genome Sciences' Failure?

Long immu isn't too smart, you sell when a stock jumps 75% after releasing skimpy data that doesn't say anything. I went short. When you see so little data, it's what the PR doesn't say not what little it did say. What were the side effects? Was there a dose response? What was the p-value? I think when the data is fully revealed it won't look so good otherwise they would have been happy to disclose it all without bias.

Regarding Garza, his articles are so bad, cut and paste when he's at his best and downhill from there once he starts giving opinions, why does anyone actually pay to subscribe to his website?